dyne therapeutics investors Navigation

Comparatively, 88.1% of Arvinas shares are held by institutional investors. J.P. Morgan, Jefferies, Piper Sandler and Stifel are underwriting the deal. Proceeds will be used to finance R&D, to develop the company's proprietary FORCE platform and for general corporate purposes. Dyne Therapeutics today announced the closing of a $115 million equity financing led by new investors Vida Ventures and Surveyor Capital. The stock's open price was 20.77. Rubius Therapeutics developed our proprietary RED PLATFORM ® to generate red blood cells and genetically engineer them into a new class of cellular medicines, called Red Cell Therapeutics™ (RCTs). WALTHAM, Mass. Stay in touch [email protected] 781.786.8230 Suite 150 La Jolla, CA 92037 [email protected] Tel: 858-401-7900 Stash allows you to purchase smaller pieces of investments, called fractional shares, rather than having to pay the full price for a whole share. Joshua Brumm, president and chief executive officer, and … Über uns Mit wallstreet:online, ariva.de, FinanzNachrichten.de und börsenNEWS.de sind wir Marktführer im Bereich Finanzinformationen. WALTHAM, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a … WALTHAM, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that Joshua Brumm, president and chief executive officer, and Romesh Subramanian, Ph.D., chief scientific officer, are scheduled to present at … Dyne Therapeutics is building a leading muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. ... and investments and companies referenced may not be suitable for all investors. Dyne Therapeutics to Present at Jefferies Virtual Healthcare Conference. A number of other institutional investors also recently modified their holdings of DYN. WALTHAM, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 … Dyne Therapeutics Option Chain There are currently 3 buy ratings for the stock. Trailblazing the development of muscle-targeted therapies— to stop or reverse disease progression Dyne Therapeutics is building a leading muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. See the full list of Tbl Law competitors, plus revenue, employees, and funding info on Owler, the world’s largest community-based business insights platform. The consensus estimate was a loss of $0.60 per share. , you can buy Dyne Therapeutics Inc stock in any dollar amount, or any other fund or stock you know on Stash. However, Dyne Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party. We designed the FORCE platform using our deep knowledge of muscle biology and oligonucleotide therapeutics to overcome the current limitations in delivery to muscle tissue with the goal of stopping … The total funding amount is around $383M. Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.The company's therapies deliver nucleic acids and other molecules to skeletal, cardiac and smooth muscle with unprecedented precision, enabling patients to restore muscle strength and transform their lives. Dyne Therapeutics to Present at Jefferies Virtual Healthcare Conference. We are building a leading muscle disease company focused on advancing innovative, life-transforming therapies for genetically driven diseases. Our initial focus is on myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). As of June 15th, investors have sold 1,840,000 shares of DYN short. Dyne Therapeutics gunning for $100M IPO weeks after a $115M raise Posted on August 27, 2020 By News Team The story of 2020 biotech startups will be told in terms of free-flowing cash, wide open public markets and early promise. Dyne Therapeutics has a market capitalization of US$963m, so we would expect some institutional investors to have noticed the stock. $5. WALTHAM, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics … Dyne Therapeutics Inc is a bio-technology company focused on providing therapeutics for patients with genetically driven diseases. Stocks News Feed provides Stock Market News, Press Releases and Investing Information from several sources. Dyne assumes no responsibility for the information, statements or other content you may encounter outside of Dyne’s website. ET. Russell Investments Group Ltd. purchased a new stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) during the first quarter, Holdings Channel.com reports. Dyne Therapeutics ( DYN) stock rose after the muscle disease company presented new preclinical data from its myotonic dystrophy type 1 (DM1) program, including results that demonstrated “sustained knockdown of toxic human nuclear DMPK RNA, the genetic basis of the disease.”. View analyst ratings for Vera Therapeutics or view top-rated stocks. Dear Shareholders: You are cordially invited to the 2021 annual general meeting of shareholders, or the 2021 Annual General Meeting of CRISPR Therapeutics AG, or the Company, to be held on June 10, 2021 at 8:00 a.m. Central European Summer Time (2:00 a.m. Eastern Daylight Time) at the offices of Walder Wyss Ltd., Seefeldstrasse 123, 8008 Zurich, Switzerland. Dyne Therapeutics to Present at Jefferies Virtual Healthcare Conference. Investors typically determine Dyne Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Dyne Therapeutics, a developer of therapies for muscle diseases, set terms for its initial public offering on Thursday, with plans to offer 10.3 million shares, priced at $16 to $18 each. Learn More on Dyne Therapeutics' current short interest. WALTHAM, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing … MPM Asset Management, LLC is the largest shareholder of the company, while 64 institutions own stock in it. WALTHAM, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management will present at upcoming virtual investor conferences. Dyne Therapeutics (DYN) Recent Earnings. The Company is utilizing its proprietary FORCE™ platform to overcome the current limitations of muscle tissue delivery with modern oligonucleotide therapeutic candidates. With a market capitalization of US$963m, Dyne Therapeutics is a decent size, so it is probably on the radar of institutional investors. Our RED PLATFORM harnesses both the unique properties of red blood cells and the creative potential of genetic engineering to deliver on the promise of cellular therapy and transform how … Dyne Therapeutics Inc., a Waltham-based muscle disease company focused on advancing innovative life-transforming therapeutics for people living … The following slide deck was published by Dyne Therapeutics, Inc. With a 5-year investment, the revenue is expected to be around +61.28%. Contact Us 10975 N. Torrey Pines Rd. Finally, Point72 Asset Management L.P. acquired a new position in Dyne Therapeutics during the first quarter worth $5,484,000. Dyne links therapeutic payloads to its TfR1-binding fragment antibody (Fab) to develop targeted therapeutics for muscle diseases. Dyne Therapeutics: United States: 1,364: 0.2: Longboard Pharmaceuticals ... Shares performed strongly after the merger as the company's visibility among investors increased. Dyne Therapeutics today announced the closing of a $115 million equity financing led by new investors Vida Ventures and Surveyor Capital. Hedge funds and other institutional investors have recently made changes to … Dyne Therapeutics, a Waltham, Mass.-based biotechnology company focused on developing life-transforming therapies for patients with serious muscle diseases, closed … Register here: https://bit.ly/3fmA4fS. Your current $100 investment may be up to $161.28 in 2026. WALTHAM, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 … About Dyne Therapeutics. In the chart below, we can see that institutions own shares in the company. Scientific Publications & Presentations. The following slide deck was published by Dyne Therapeutics, Inc. ... Dyne Therapeutics (DYN) Investor Presentation - … Trailblazing the development of muscle-targeted therapies— to stop or reverse disease progression Dyne Therapeutics is building a leading muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. Net loss: Net loss was $13.9 million or $2.01 per common share for the third quarter 2020 compared to $5.9 million, or $2.36 per common share for the third quarter 2019. $50. Comparatively, 16.8% of Trevena shares are held by institutional investors. Kinder Morgan has confirmed that its next quarterly earnings report will be published on Wednesday, July 21st, 2021. –­­­ Dyne Therapeutics, a biotechnology company pioneering targeted therapies for patients with serious muscle diseases, today announced an equity investment from CureDuchenne Ventures.The funding will support Dyne’s development of precision therapeutics designed to restore muscle health in people living with Duchenne muscular dystrophy (DMD). For Dyne Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Dyne Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. 6.81% of Dyne Therapeutics' shares are currently sold short. The consensus among Wall Street analysts is that investors should "buy" Vera Therapeutics stock. Dyne Therapeutics (DYN) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement. The institutional investor purchased 7,023 shares of the company’s stock, valued at approximately $109,000. 781.786.8230. Vida Ventures, a Los Angeles, CA- and Boston, MA-based life sciences venture capital firm, closed Vida Ventures III, L.P., at $825m.. Dyne is an opportunity to take cutting-edge nucleic acid-based therapeutics and use our understanding of human biology to overcome the next set of hurdles in precision medicine. Life sciences venture capital firm Vida Ventures said on Thursday it had raised $825 million in an oversubscribed funding round for its third fund … On World FSHD Day and every day, Dyne is dedicated to making a difference by advancing potentially life-transforming therapies for individuals and families living with FSHD. We are building a leading muscle disease company focused on advancing innovative, life-transforming therapies for genetically driven diseases. Shares of DYN were up 3.24% to $17.53 per share on Friday afternoon. Mit über 20 Jahren Erfahrung haben wir einen Broker entwickelt, der auf die Bedürfnisse der Anleger zugeschnitten ist. Dyne Therapeutics, Inc. dropped from Russell 3000 Growth Index... | July 22, 2021 WALTHAM, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the first quarter 2021 and business highlights. Dyne Therapeutics Dyne Therapeutics is building a leading muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. WALTHAM, Mass., August 10, 2020 – Dyne Therapeutics, a biotechnology company focused on developing life-transforming therapies for patients with serious muscle diseases, today announced the closing of a $115 million equity financing led by new investors Vida Ventures and Surveyor Capital (a Citadel company). For Dyne Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Dyne Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. Get the latest Dyne Therapeutics, Inc. DYN detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. However, Dyne Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party. For Dyne Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Dyne Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. WALTHAM, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a … Dyne Therapeutics, Inc. (NASDAQ:DYN)’s Biggest Investors Dyne Therapeutics, Inc. insiders own 6.57% of total outstanding shares while institutional holders control 77.69%, with the float percentage being 83.15%. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue seen with other approaches. Kinder Morgan has generated $0.88 earnings per share over the last year and currently has a price-to-earnings ratio of 21.6. We are building a leading muscle disease company focused on advancing innovative, life-transforming therapies for genetically driven diseases. The team being built at Dyne is perfectly positioned to develop novel therapeutics for rare diseases, and I am ecstatic to have the opportunity to be a part of it. In the chart below, we can see that institutions own shares in the company. Stay up to date with lastest Earnings Announcements for Dyne Therapeutics, Inc. from Zacks Investment Research Last venture funding round was $168M, announced on January, 2021. DYN: Dyne Therapeutics, Inc. - Earnings Announcements. The company is advancing a … Citigroup Inc. purchased a new position in Dyne … Stifel is reiterating a buy rating on shares of Fulcrum and doubling its price target from $20 to $39 following phase 2 data on the company's candidate for a type of muscular dystrophy. Comparatively, 2.7% of Trevena shares are held by insiders. Dyne Therapeutics Inc stock is down -13.35% since Thursday, September 17, 2020 when the stock began trading, and the average rating from Wall Street analysts is a Strong Buy.InvestorsObserver’s proprietary ranking system, gives DYN stock a score of 30 out of a possible 100.. That rank is influenced by a long-term technical score of 0. That percentile equates to a POWR Industry Rating of F (Strong Sell). Dyne’s DM1 lead candidate consists of a Fab conjugated to an antisense oligonucleotide (ASO) to enable targeted delivery to muscle tissue to … WALTHAM, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics … Dyne Therapeutics to Present at Jefferies Virtual Healthcare Conference. Dyne Therapeutics is building a leading muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. [email protected]. Funding & investors Dyne Therapeutics has received 3 rounds of venture funding. focused on muscle diseases. Dyne Therapeutics Invested Capital Average yearly trend continues to be quite stable with very little volatility. If the real value is higher than the market price, Dyne Therapeutics is considered to be undervalued, and we provide a buy recommendation. Dyne Therapeutics, a biotechnology company focused on developing life-transforming therapies for patients with serious muscle diseases, today announced the closing of a $115 million equity financing led by new investors Vida Ventures and Surveyor Capital (a Citadel company). WALTHAM, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 9:00 a.m. TfR1, which is highly expressed on the surface of muscle cells, is required for iron transport into muscle cells. Dyne Therapeutics has a 1-year low of $13.50 and a 1-year high of $32.31. She was involved in the launch of two companies, Quench Bio and Dyne Therapeutics, and served on several boards including Navitor, Quench, and Dyne. 42.7% of Dyne Therapeutics shares are held by insiders. Most of Dyne Therapeutics' fundamental indicators, such as Number of Employees, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. $25. Gonzalez Calvillo acted as Mexican counsel to investors, while Creel García – Cuellar, Aiza y Enríquez – as Mexican counsel to Fibra Prologis in the transaction. June 25, 2021. Comparatively, 11.0% of Arvinas shares are held by company insiders. A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. WALTHAM, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for patients with genetically driven diseases, today announced the closing of its initial public offering of 14,089,314 shares of its common stock at an initial public offering price of $19.00 per share, including 1,837,736 … The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. Investor Relations Dyne ... Dyne Therapeutics Inc is a bio-technology company focused on providing therapeutics for patients with genetically … View Dyne Therapeutics, Inc. DYN investment & stock information. The data on short interest also indicates that stock shorts accounted for 1.98 Million shares as on April 14, 2021, resulting in a short ratio of 8.11. Dyne Therapeutics Announces Pricing of Initial Public Offering. Kinder Morgan will be holding an earnings conference call on Wednesday, July 21st at 4:30 PM Eastern. WALTHAM, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a … Investors typically determine Dyne Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In the chart below, we … Let's take a closer look to see what the different types of shareholders can tell us about Dyne Therapeutics. 65.78% of the stock is owned by institutional investors and hedge funds. Investors who participated in the round include sovereign wealth funds, endowments and foundations, pensions, financial institutions, family offices and individuals. Prior to joining Dyne, Dr. Dugar served as vice president and global head of medical affairs at Sarepta Therapeutics, Inc., where he built the company’s medical affairs organization. Sustainable Investing; Advisor Insights; Personal Finance; Market Volatility; Retirement Planning; Start Investing; Save for College; See All Atlas Venture (Venture capital) MPM Capital (Private equity firm) The company has a 50-day simple moving average of $18.90. The Investor Relations website contains information about Dyne Therapeutics's business for stockholders, potential investors, and financial analysts. July 21, 2021 Los Grobo Agropecuaria’s $80 Million Medium Term Notes Program Which institutional investors are buying and selling shares of Dyne Therapeutics (NASDAQ:DYN) stock? Dyne Therapeutics ( DYN) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement. Dyne Therapeutics has a market capitalization of US$963m, so we would expect some institutional investors to have noticed the stock. Based on our forecasts, a long-term increase is expected, the "DYN" stock price prognosis for 2026-07-01 is 33.886 USD. DYN, Dyne Therapeutics Inc - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines Dyne Therapeutics Inc Stock Quote: DYN Stock News, Quotes, Analysis | Investors.com Dyne Therapeutics. Dyne Therapeutics Inc., ... Realty Boston Metro in the Back Bay where she provided real estate services and representation for buyers, sellers, investors, landlords, tenants and developers. Let's take a closer look to see what the different types of shareholders can tell us about Dyne Therapeutics. For Dyne Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Dyne Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. WALTHAM, Mass., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for patients with genetically driven diseases, today announced the pricing of its initial public offering of 12,251,578 shares of its common … View the most recent institutional ownership activity and 13F transactions for DYN stock at MarketBeat. Dyne Therapeutics (DYN) intends to raise $175 million from the sale of its common stock in an IPO, Biotech is the #117 ranked industry out of 124, which means it is in the 6 percentile of all industries we cover. Dyne Therapeutics, Inc quote is equal to 21.010 USD at 2021-07-12. 42.7% of Dyne Therapeutics shares are held by company insiders. View the latest Dyne Therapeutics Inc. (DYN) stock price, news, historical charts, analyst ratings and financial information from WSJ. The stock has a market cap of $1.12 billion and a P/E ratio of -5.32. DYN's rank also includes a short-term … Short interest is the volume of Dyne Therapeutics shares that have been sold short but have not yet been closed out or covered. Dyne Therapeutics (DYN) reported a 1st Quarter March 2021 loss of $0.50 per share on revenue of $0.0 million. Dr. Dugar brings to Dyne over 20 years of broad experience across medical affairs, clinical and commercial development, and real-world evidence (RWE) generation. Investors & Media Dyne Therapeutics is building a leading muscle disease company dedicated to advancing innovative life-transforming therapeutics for people living with genetically driven diseases. Nearly 2.7% of Dyne Therapeutics, Inc.’s shares belong to company insiders and institutional investors own 88.71% of the company’s shares, according to Thomson Reuters’ data. Dyne Therapeutics Inc Ordinary Shares DYN ... We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of … Dyne Therapeutics Stock Options and stock option analytics, including greeks and implied volatility. Join us for the Next Gen Exon Skipping Panel, hosted by Eric Camino, in which we’ll be discussing our DMD program. Dyne Therapeutics stock news, alerts, and headlines are usually related to their technical, predictive, social, and fundamental indicators. Dyne Therapeutics is selling for 21.01 as of the 10th of July 2021. Today at 3:25 PM EST, we are participating in a panel at the Parent Project Muscular Dystrophy conference. Dyne Therapeutics, a new biotechnology company pioneering targeted therapies for patients with serious muscle diseases, launched today with a $50 mill ... Its investors … It can reflect on the current distribution of Dyne Therapeutics daily returns and investor perception about the current pice of Dyne Therapeutics as well as its diversification or hedging effects on your existing portfolios. She was previously an investor and EIR at the US-based fund, Atlas Venture, where she focused on company creation, early-stage investing, and operations within Atlas portfolio companies. The value of Invested Capital Average is projected to decrease to about 12.4 B.From the period between 2010 and 2021, Dyne Therapeutics, Invested Capital Average regression line of its data series had standard deviation of 5,015,197,166 and standard deviation of Dyne Therapeutics, a biotechnology company focused on developing life-transforming therapies for patients with serious muscle diseases, today announced the closing of a $115 million equity financing led by new investors Vida Ventures and Surveyor Capital (a Citadel company).Additional new investors, including Wellington Management Company, Logos Capital, Franklin Templeton and an … Dyne Therapeutics Inc (NASDAQ: DYN) has announced new preclinical data from its myotonic dystrophy type 1 (DM1) program, including results demonstrating sustained knockdown of … Their latest funding was raised on Jan 21, 2021 from a Post-IPO Equity round. WALTHAM, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics … WALTHAM, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics … You are also invited to Sign Up and join the Groups and Activity chats. FORCE ™ Platform Enables Muscle-Targeted Delivery of Antisense Oligonucleotide and Silencing of DUX4 Activity in an FSHD Cell Line Presented at 28th Annual FSHD Society International Research Congress, June 25, … The Investor Relations website contains information about Dyne Therapeutics's business for stockholders, potential investors, and financial analysts. This is a 1.16 percent increase since the beginning of the trading day. Dyne Therapeutics, a developer of therapies for muscle diseases, set terms for its initial public offering on Thursday, with plans to offer 10.3 million shares, priced at $16 to $18 each. The company has applied to list on Nasdaq, under the ticker "DYN." Robinhood allows investors to purchase fractional shares, which lowers the barrier to the stock market. The company is advancing a … Get the latest Dyne Therapeutics detailed stock quotes, stock trade data, stock price info, and performance analysis, including Dyne Therapeutics Stock investment advice, charts, stats and more. Dyne Therapeutics financials, including financial statements for 2021, basic ratios and analysis of Dyne Therapeutics account historical trends WALTHAM, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that new preclinical data from its myotonic dystrophy type 1 (DM1) program will be featured in presentations during the American Society of Gene …